PSTXPoseida Therapeutics, Inc.

Nasdaq poseida.com


$ 2.92 $ -0.14 (-4.58 %)    

Tuesday, 27-Aug-2024 13:47:34 EDT
QQQ $ 477.15 $ 2.69 (0.57 %)
DIA $ 412.70 $ 0.43 (0.11 %)
SPY $ 561.79 $ 2.65 (0.47 %)
TLT $ 97.89 $ 0.32 (0.33 %)
GLD $ 233.02 $ 1.35 (0.58 %)
$ 3.06
$ 2.96
$ 2.88 x 100
-- x --
$ 2.88 - $ 2.96
$ 1.83 - $ 4.27
494,312
na
297.19M
$ 1.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-07-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-09-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-10-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-11-2021 03-31-2021 10-Q
15 03-11-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-20-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

 poseida-therapeutics-q2-eps-032-beats-041-estimate-sales-2597m-beat-1543m-estimate

Poseida Therapeutics (NASDAQ:PSTX) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

 hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

 poseida-therapeutics-q1-2024-adj-eps-025-beats-042-estimate-sales-2814m-beat-1167m-estimate

Poseida Therapeutics (NASDAQ:PSTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of ...

 poseida-highlights-progress-on-its-genetic-medicine-programs-at-the-american-society-for-gene-and-cell-therapy-27th-annual-meeting

Early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic rang...

 hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

Core News & Articles

- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid ...

 astellas-and-poseida-therapeutics-enter-into-research-collaboration-and-license-agreement-to-develop-novel-allogeneic-cell-therapies-in-oncology

- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid ...

 hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

 poseida-therapeutics-presents-new-phase-1-data-at-aacr-2024-supporting-potential-of-p-bcma-allo1-allogeneic-car-t-therapy-to-benefit-broad-range-of-patients-with-multiple-myeloma

Promising early data suggest patients with relapsed/refractory multiple myeloma who progressed after prior BCMA-targeted therap...

 why-mesoblast-shares-are-trading-higher-by-13-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an ...

 eqt-genie-energy-and-other-big-stocks-moving-lower-on-monday

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

 hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION